A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine

Over 95% of Pancreatic ductal adenocarcinomas (PDA) carry mutations in the oncogene KRas which has been proven to be a difficult drug target. P21-activated kinase 4 (PAK4), acts downstream of KRas, and is overexpressed in PDA contributing to its growth and chemoresistance, and thus becomes an attrac...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Hong, Dumesny, Chelsea, Ang, Ching-Seng, Dong, Li, Ma, Yi, Zeng, Jun, Nikfarjam, Mehrdad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724943/
https://www.ncbi.nlm.nih.gov/pubmed/34973571
http://dx.doi.org/10.1016/j.tranon.2021.101329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724943/
https://www.ncbi.nlm.nih.gov/pubmed/34973571
http://dx.doi.org/10.1016/j.tranon.2021.101329

Ejemplares similares